International organisations have joined forces to challenge the European patent for Gilead’s hepatitis C drug sofosbuvir. Medecins Sans Frontieres (MSF) and Medecins du Monde (MdM) said its high cost was a serious barrier to access for many patients. And according to the organisations the patent is open to challenge because the science behind the drug ...
Hep C drug patent challenged in Europe
4 Apr 2017